

Cytogenetic Studies

CPT: 88230, 88235, 88237, 88249, 88262, 88263, 88264, 88269, 88271, 88273, 88274, 88275, 88280, 88289, 88291

CMS National Coverage Policy

Coverage Indications, Limitations, and/or Medical Necessity

The term cytogenetic studies is used to describe the microscopic examination of the physical appearance of human chromosomes.

Indications and Limitations of Coverage Medicare covers these tests when they are reasonable and necessary for the diagnosis or treatment of the following conditions:

- Genetic disorders (e.g., mongolism) in a fetus; (See the Medicare Benefit Policy Chapter 15, "Covered Medical and Other Health Services," §20.1)
- Failure of sexual development;
- Chronic myelogenous leukemia;
- Acute leukemias lymphoid (FAB L1-L3), myeloid (FAB M0-M7), and unclassified; or
- Myelodysplasia

Visit [QuestDiagnostics.com/MLCP](https://www.questdiagnostics.com/MLCP) to view current limited coverage tests, reference guides, and policy information.

To view the complete policy and the full list of codes, please refer to the CMS website reference

www.cms.gov ►

Cytogenetic Studies

CPT: 88230, 88235, 88237, 88249, 88262, 88263, 88264, 88269, 88271, 88273, 88274, 88275, 88280, 88289, 88291

The ICD10 codes listed below are the top diagnosis codes currently utilized by ordering physicians for the limited coverage test highlighted above that are also listed as medically supportive under Medicare's limited coverage policy. **If you are ordering this test for diagnostic reasons that are not covered under Medicare policy, an Advance Beneficiary Notice form is required.**

***Note—Bolded diagnoses below have the highest utilization**

Please refer to the [Limitations or Utilization Guidelines](#) section on previous page(s) for frequency information.

Code	Description
C91.00	Acute lymphoblastic leukemia not having achieved remission
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission
C92.41	Acute promyelocytic leukemia, in remission
C92.52	Acute myelomonocytic leukemia, in relapse
C93.10	Chronic myelomonocytic leukemia not having achieved remission
C95.00	Acute leukemia of unspecified cell type not having achieved remission
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.21	Refractory anemia with excess of blasts 1
D46.4	Refractory anemia, unspecified
D46.9	Myelodysplastic syndrome, unspecified
D72.0	Genetic anomalies of leukocytes
E29.1	Testicular hypofunction
Q93.89	Other deletions from the autosomes
Q95.0	Balanced translocation and insertion in normal individual
Q96.9	Turner's syndrome, unspecified
Q98.4	Klinefelter syndrome, unspecified
Z13.79	Encounter for other screening for genetic and chromosomal anomalies
Z15.09	Genetic susceptibility to other malignant neoplasm
Z15.89	Genetic susceptibility to other disease

Visit [QuestDiagnostics.com/MLCP](https://www.questdiagnostics.com/MLCP) to view current limited coverage tests, reference guides, and policy information.

To view the complete policy and the full list of medically supportive codes, please refer to the CMS website reference

www.cms.gov

Last updated: 10/01/21

Disclaimer:

This diagnosis code reference guide is provided as an aid to physicians and office staff in determining when an ABN (Advance Beneficiary Notice) is necessary. Diagnosis codes must be applicable to the patient's symptoms or conditions and must be consistent with documentation in the patient's medical record. Quest Diagnostics does not recommend any diagnosis codes and will only submit diagnosis information provided to us by the ordering physician or his/her designated staff. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2016 Quest Diagnostics Incorporated. All rights reserved.